Surgimab
  • Science
    • Technology
    • Pipeline
    • Clinical trials
    • Publications
  • About SurgiMab
    • History
    • Our team
    • Partners
  • News
  • Contact
Select Page
SurgiMab announces recruitment of first US patient in pivotal Phase 3 clinical trial evaluating SGM-101 in colorectal cancer patients

SurgiMab announces recruitment of first US patient in pivotal Phase 3 clinical trial evaluating SGM-101 in colorectal cancer patients

by kwal1 | Oct 17, 2019 | News

SGM-101 could provide a new approach for patients diagnosed with CRC, most of whom undergo surgery. Montpellier, France, 17 octobre 2019 – SurgiMab today announces that the first US patient has been recruited in its pivotal Phase 3 clinical trial of SGM-101, in a...
SurgiMab advances SGM-101 into pivotal Phase 3 clinical trial to improve surgical outcomes in colorectal cancer patients

SurgiMab advances SGM-101 into pivotal Phase 3 clinical trial to improve surgical outcomes in colorectal cancer patients

by kwal1 | Jul 16, 2019 | News

SGM-101 has the potential to be the first tumor-targeted fluorescent probe to be marketed for fluorescence-guided surgery (FGS). Montpellier, France, 16 July 2019 – SurgiMab today announces that the first surgical procedure was carried out in a pivotal Phase 3...
SGM-101 Clinical Results in Colorectal Cancer published in the Lancet Gastroenterology & Hepatology

SGM-101 Clinical Results in Colorectal Cancer published in the Lancet Gastroenterology & Hepatology

by kwal1 | Jan 31, 2018 | News

Dr. Alex Vahrmeijer’s team in Leiden publishes first results of the clinical use of SGM-101. Montpellier, France 31st Jan 2018 – SurgiMab is very proud to announce that Dr. Alex Vahrmeijer’s team in Leiden University Medical Center (LUMC) published their...
SurgiMab sponsors the “Molecular Guided Surgery” conference of the SPIE Photonics West meeting in San Francisco 27-28 January 2018

SurgiMab sponsors the “Molecular Guided Surgery” conference of the SPIE Photonics West meeting in San Francisco 27-28 January 2018

by kwal1 | Jan 11, 2018 | News

SurgiMab sponsors the Molecular Guided Surgery conference that will take place during the SPIE Photonics West in San Francisco, 27-28 Jan 2018. Montpellier, France Jan 2018 – SurgiMab is proud to be a sponsor of the Molecular Guided Surgery conference that will take...
SurgiMab and Quest Medical Imaging announce Collaboration Agreement for phase III Clinical Trial

SurgiMab and Quest Medical Imaging announce Collaboration Agreement for phase III Clinical Trial

by kwal1 | Sep 19, 2017 | News

SurgiMab and Quest Medical Imaging enter a Collaboration Agreement for the 1st Phase III multicenter clinical trial on Fluorescence Guided Surgery for Digestive Cancers. Montpellier, France and Mid­den­meer, Holland – 18 sept 2017 – SurgiMab and Quest Medical...
« Older Entries
Next Entries »

Articles récents

  • SurgiMab Honored with the “Tech for Future 2025” Award in Healthcare by La Tribune, France – April 2, 2025
  • Françoise Cailler, CEO of surgiMab, will attend the WMIC2024 Congress in Montreal
  • SurgiMab will sponsor the next edition of the International Symposium on Fluorescence Guided Surgery, 2-3 Nov 2023 in Amsterdam
  • SurgiMab will participate to the conference “Optics in the Life Sciences” during the Optica Biophotonics Congress in Vancouver April 23 – 27, 2023
  • SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.

Commentaires récents

No comments to show.

Contact

Francoise Cailler: +33 467 798 381
Michel Barbelanne: +33 467 798 382

Legal

Legals, privacy & cookies

  • Science
    • Technology
    • Pipeline
    • Clinical trials
    • Publications
  • About SurgiMab
    • History
    • Our team
    • Partners
  • News
  • Contact